Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru JUN 2010
    - OnBioVC 2Q10 Trend Analysis, now available
    - OnBioVC 3Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • investment bank middle market venture capital

Aptus Endosystems (Sunnyvale, CA) a clinical-stage medical device company focused on endovascular aneurysm repair, closed a $15M Series D financing. Participants include US Venture Partners and Longitude Capital.

Solazyme (San Francisco, CA) a development-stage synthetic biology company focused on algal biodiesel and industrial chemicals, closed a $52M Series D financing. Participants include Morgan Stanley Venture Partners, Braemar Energy Ventures, Lightspeed Venture Partners, Roda Group, Harris and Harris Group, VantagePoint Venture Partners, Zygote Ventures, Chevron Technology Venture Investments and San-Ei Gen.

BarRx Medical (Sunnyvale, CA) a clinical-stage medical device company focused on endoscopic treatment of precancerous lesions of the esophagus and other chronic gastrointestinal diseases, closed a $15M Series financing. Participants include Highland Capital Partners, Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures and Greenspring Associates.

Ventus Medical (Belmont, CA) a commercial-stage medical device company focused on obstructive sleep apnea, closed a $40M Series D financing. Participants were not identified.

Reata Pharmaceuticals (Irving, TX) a clinical-stage small molecule company focused on inflammation modulation in chronic kidney disease, closed a $78M Series D financing. Participants include CPMG and Novo Ventures.

Zeltiq (Pleasanton, CA) a commercial-stage medical device company focused on lipolysis for fat reduction and other dermatological applications, closed a $25M Series D financing. Participants include Aisling Capital, Venrock, Frazier Healthcare Ventures and Advanced Technology Ventures.

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Phreesia (New York, NY) a commercial-stage developer of patient intake data, closed a $16M Series D financing. Participants include Ascension Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

Coskata (Warrenville, IL) a development-stage bacterial fermentation biofuels company closed a $23.7M Series D financing. Participants include Total, Blackstone Group, Advanced Technology Ventures, Globespan Capital Partners, General Motors, GreatPoint Ventures and Khosla Ventures.

BioScale (Cambridge, MA) a commercial-stage therapeutic and diagnostics protein biomarker analytics device company, closed a $25M Series D financing. Participants include Morningside Venture, New Science Ventures, WFD Ventures and F2 Ventures.

« Previous Entries  

to top of page...